Welcome to our dedicated page for Apyx Medical news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical stock.
Apyx Medical Corporation reports news on its surgical aesthetics medical-device business, including products marketed as Renuvion, the AYON Body Contouring System, and J-Plasma. Updates commonly cover FDA 510(k) clearances, body contouring capabilities, controlled-heat tissue applications, commercial activity in cosmetic surgery and hospital surgical markets, and OEM agreements with other medical device manufacturers.
The company’s recurring financial releases discuss revenue by its Surgical Aesthetics and Original Equipment Manufacturing segments, product demand for generators and single-use handpieces, U.S. and international sales trends, and management conference participation.
Apyx Medical Corporation (NASDAQ:APYX) has granted a nonstatutory stock option to John Featherstone, the company's Vice President of North American Sales, as part of his employment inducement. The stock option allows for the purchase of 100,000 shares of common stock at an exercise price of $1.85 per share, based on the closing price on August 4, 2025.
The stock option features a four-year vesting schedule, with 25% of shares vesting on the first anniversary and the remainder vesting annually thereafter, contingent upon continued employment. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion® and AYON Body Contouring System™ for cosmetic surgery, and J-Plasma® for hospital surgical applications.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology and manufacturer of Renuvion® and AYON Body Contouring System™, has announced two key executive appointments to strengthen its global sales leadership. John Featherstone joins as Vice President of North American Sales, bringing over 20 years of aesthetics and medical device industry experience. Simon Davies has been appointed as Director of International Sales for Europe and Asia-Pacific, contributing 30 years of global sales leadership expertise.
These strategic hires are aimed at supporting the commercial launch of AYON, the industry's first all-in-one surgical body contouring system, and accelerating the company's global expansion efforts. The appointments align with Apyx's commitment to scaling its commercial operations and enhancing market penetration across key regions.
Apyx Medical (NASDAQ:APYX) reported Q2 2025 financial results with total revenue of $11.4 million, down from $12.1 million year-over-year. The company highlighted the successful launch of its AYON Body Contouring System™ and initiated Renuvion® sales in China.
Key financials include a reduced net loss of $3.8 million (down 42% YoY) and an Adjusted EBITDA loss of $2.0 million (improved 54% YoY). Following strong AYON pre-sales, Apyx increased its FY2025 revenue guidance to $50.0-52.0 million, up from previous guidance of $47.6-49.0 million.
Advanced Energy segment revenue remained relatively flat at $9.7 million, while OEM revenue decreased 28.5% to $1.7 million. The company plans a full commercial launch of AYON in September 2025.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology, announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA.
CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and hold one-on-one investor meetings throughout the day. The presentation will be available via live webcast with a replay option on the company's investor relations website.
Apyx Medical specializes in Helium Plasma Platform Technology, marketing Renuvion® and AYON Body Contouring System™ for cosmetic surgery and J-Plasma® for hospital surgical markets, with efficacy supported by over 90 clinical publications.
[]Apyx Medical Corporation (NASDAQ:APYX) has announced the launch of its Renuvion® technology in China, marking a significant expansion into one of the world's largest healthcare markets. The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC), following initial market clearance from China's National Medical Products Administration.
The partnership with BCC, which operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities, positions Renuvion for significant market penetration. Early clinical interest and completed procedures indicate strong market potential for Apyx's helium plasma technology, which is supported by more than 90 clinical documents.
Apyx Medical Corporation (NASDAQ:APYX), a manufacturer of advanced helium plasma and radiofrequency technology, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 4:30 PM ET the same day.
Apyx Medical specializes in the Renuvion® and AYON Body Contouring System™ for the cosmetic surgery market, and J-Plasma® for hospital surgical applications. Their technology's effectiveness is backed by over 90 clinical publications, demonstrating their strong presence in the advanced energy technology sector.
Apyx Medical Corporation (NASDAQ:APYX) has announced television personality Dolores Catania as Chief of Confidence for their Renuvion brand's Renew You consumer marketing campaign. Catania, known from "The Real Housewives of New Jersey" and "The Traitors," will represent the brand's body contouring technology across marketing initiatives including social media, PR, and physician events.
Renuvion is the only FDA-cleared device for use after liposuction and is backed by over 90 clinical publications. The technology is recognized as the #1 body contouring solution trusted by doctors for addressing loose skin concerns, with 4 out of 5 surgeons agreeing in an independent survey. Catania, who has personal experience with the treatment, will leverage her journey with weight loss and transformation to promote the brand's message of physical and emotional empowerment.